# Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)

> **NCT06354179** · PHASE4 · RECRUITING · sponsor: **University Hospital, Limoges** · enrollment: 162 (estimated)

## Conditions studied

- Liver Transplantation
- Immunosuppression

## Interventions

- **DRUG:** XR-tacrolimus QD + MMF BID then MMF QD
- **DRUG:** XR-tacrolimus QD + MMF BID
- **DRUG:** LCP-tacrolimus QD + MMF QD then MMF QD
- **DRUG:** LCP-tacrolimus QD + MMF BID

## Key facts

- **NCT ID:** NCT06354179
- **Lead sponsor:** University Hospital, Limoges
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2028-04-15
- **Final completion:** 2028-04-15
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06354179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06354179, "Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT06354179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*